Literature DB >> 22521335

New insights on endocannabinoid transmission in psychomotor disorders.

Andrea Giuffrida1, Alexandre Seillier.   

Abstract

The endocannabinoids are lipid signaling molecules that bind to cannabinoid CB(1) and CB(2) receptors and other metabotropic and ionotropic receptors. Anandamide and 2-arachidonoyl glycerol, the two best-characterized examples, are released on demand in a stimulus-dependent manner by cleavage of membrane phospholipid precursors. Together with their receptors and metabolic enzymes, the endocannabinoids play a key role in modulating neurotransmission and synaptic plasticity in the basal ganglia and other brain areas involved in the control of motor functions and motivational aspects of behavior. This mini-review provides an update on the contribution of the endocannabinoid system to the regulation of psychomotor behaviors and its possible involvement in the pathophysiology of Parkinson's disease and schizophrenia.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521335      PMCID: PMC3389227          DOI: 10.1016/j.pnpbp.2012.04.002

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  177 in total

1.  Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway.

Authors:  Gabriel M Simon; Benjamin F Cravatt
Journal:  J Biol Chem       Date:  2006-07-03       Impact factor: 5.157

2.  Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex.

Authors:  S M Eggan; D S Melchitzky; S R Sesack; K N Fish; D A Lewis
Journal:  Neuroscience       Date:  2010-06-11       Impact factor: 3.590

Review 3.  Evidence for novel cannabinoid receptors.

Authors:  Malcolm Begg; Pál Pacher; Sándor Bátkai; Douglas Osei-Hyiaman; László Offertáler; Fong Ming Mo; Jie Liu; George Kunos
Journal:  Pharmacol Ther       Date:  2005-01-11       Impact factor: 12.310

4.  Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens.

Authors:  Virgina M Pickel; Jane Chan; Christopher S Kearn; Kenneth Mackie
Journal:  J Comp Neurol       Date:  2006-03-20       Impact factor: 3.215

5.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury.

Authors:  D Panikashvili; C Simeonidou; S Ben-Shabat; L Hanus; A Breuer; R Mechoulam; E Shohami
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

6.  A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.

Authors:  Natasha T Snider; James A Nast; Laura A Tesmer; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2009-01-26       Impact factor: 4.436

Review 7.  Role of endogenous cannabinoids in synaptic signaling.

Authors:  Tamas F Freund; Istvan Katona; Daniele Piomelli
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

8.  Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.

Authors:  C B Carroll; P G Bain; L Teare; X Liu; C Joint; C Wroath; S G Parkin; P Fox; D Wright; J Hobart; J P Zajicek
Journal:  Neurology       Date:  2004-10-12       Impact factor: 9.910

9.  Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Authors:  F Markus Leweke; Andrea Giuffrida; Dagmar Koethe; Daniela Schreiber; Brit M Nolden; Laura Kranaster; Miriam A Neatby; Miriam Schneider; Christoph W Gerth; Martin Hellmich; Joachim Klosterkötter; Daniele Piomelli
Journal:  Schizophr Res       Date:  2007-06-13       Impact factor: 4.939

10.  Endocannabinoid signalling in the blood of patients with schizophrenia.

Authors:  Nicola De Marchi; Luciano De Petrocellis; Pierangelo Orlando; Fabiana Daniele; Filomena Fezza; Vincenzo Di Marzo
Journal:  Lipids Health Dis       Date:  2003-08-19       Impact factor: 3.876

View more
  6 in total

1.  Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs.

Authors:  Antoni Pastor; Magí Farré; Montserrat Fitó; Fernando Fernandez-Aranda; Rafael de la Torre
Journal:  J Lipid Res       Date:  2014-03-07       Impact factor: 5.922

2.  Peripheral endocannabinoid system dysregulation in first-episode psychosis.

Authors:  Miquel Bioque; Borja García-Bueno; Karina S Macdowell; Ana Meseguer; Pilar A Saiz; Mara Parellada; Ana Gonzalez-Pinto; Roberto Rodriguez-Jimenez; Antonio Lobo; Juan C Leza; Miguel Bernardo
Journal:  Neuropsychopharmacology       Date:  2013-07-04       Impact factor: 7.853

Review 3.  Hub and switches: endocannabinoid signalling in midbrain dopamine neurons.

Authors:  Miriam Melis; Marco Pistis
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

Review 4.  Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research.

Authors:  Rafael N Ruggiero; Matheus T Rossignoli; Jana B De Ross; Jaime E C Hallak; Joao P Leite; Lezio S Bueno-Junior
Journal:  Front Pharmacol       Date:  2017-06-21       Impact factor: 5.810

5.  Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model.

Authors:  Alexandre Seillier; Alex A Martinez; Andrea Giuffrida
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

Review 6.  Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction.

Authors:  Stéphanie Olière; Antoine Joliette-Riopel; Stéphane Potvin; Didier Jutras-Aswad
Journal:  Front Psychiatry       Date:  2013-09-23       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.